Recon: Novo Holdings slated to buy Catalent for $16.5B; Amgen, Regeneron pursuing GLP-1 class obesity drugs
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States